Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET
Company Participants
Brian M. Goff – CEO & Director
Cecilia Jones – Chief Financial Officer
Sarah Gheuens – Chief Medical Officer and Head of Research & Development
Tsveta Milanova – Chief Commercial Officer
Morgan Sanford – Vice President, Investor Relations
Conference Call Participants
Andrew Scott Berens – Leerink Partners LLC, Research Division
Emily Claudia Bodnar – H.C. Wainwright & Co, LLC, Research Division
Marc Alan Frahm – TD Cowen, Research Division
Salveen Jaswal Richter – Goldman Sachs Group, Inc., Research Division
Tessa Thomas Romero – JPMorgan Chase & Co, Research Division
Morgan Sanford – Vice President of Investor Relations
Operator
Good morning, and welcome to Agios’ Second Quarter 2025 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Agios’s request.
I would now like to turn the call over to Agio. Please go ahead.
Morgan Sanford
Thank you, operator. Good morning, everyone. I’m Morgan Sanford, Vice President of Investor Relations at Agios. Thank you for joining us to discuss Agios Pharmaceuticals Second Quarter 2025 Financial Results and Business Highlights. You can access the slides for today’s call by going to the Investors section of our website, agios.com. Please move to the next slide.
Today, we’ll be making certain forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements. Because of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC. Next slide, please.
On the call with me today from Agios are Brian Goff, Chief Executive Officer; Cecilia Jones, Chief Financial Officer; Tsveta Milanova, Chief Commercial Officer; and Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development. Following prepared
#Agios #Pharmaceuticals #AGIO #Earnings #Call #Transcript